en · de · es · fr · pt
semax-notes.peptides6088.com › News › Semax �š„储存、稳定性与分析 — Practical Notes

Semax �š„储存、稳定性与分析 — Practical Notes

By Editorial Desk · published 2026-05-23 · last reviewed 2026-06-27 · News

If you have been reading about intranasal route and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-06-27. Numbers and descriptions here follow the published literature rather than marketing material.

Semax 的储存、稳定性与分析

多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下,同时避免光照与反复升温。短期运输有时采用冷藏条件,但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数,以降低吸湿和微生物污染的风险。开封后若未一次用完,建议在干燥环境中密封并尽快放回低温储存。

溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集,其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸,因此氧化风险相对突出。工作液一般主张现配现用,或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率,而关于最佳条件的公开数据并不统一。

常规纯度与身份确认依赖反相高效液相色谱,并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成,肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同,因此各实验室报告的纯度数值不宜直接横向比较。

Semax Peptide Background and Identity

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax at a glance

PropertyValueNotes
外观白色至类白色粉末常见于冻干制剂
溶解度易溶于水在极性溶剂中一般也可溶
建议储存温度-20 °C冻干粉,避光密封
常见分析手段反相高效液相色谱常与质谱联用
主要降解路径水解与氧化溶液状态更显著

Storage Handling and Analytical Verification

Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.

Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.

Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.

Related pages on this site

Semax Structure and Research Background

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Mechanisms and Research Directions

Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.

Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.

Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.

Further detail

== Further reading == Mulier, Jan P.; Hunter, Jennifer M.; de Boer, Hans D. (February 2021). "Seventy-five years since the birth of the Liverpool anaesthetic technique". Editorial. British Journal of Anaesthesia. 126 (2): 343–347. doi:10.1016/j.bja.2020.10.020. Donohue, Ciara; Hobson, Ben; Stephens, Robert C. M. (May 2013). "An introduction to anaesthesia" (PDF). British Journal of Hospital Medicine. 74 (5): C71-5. doi:10.12968/hmed.2013.74.Sup5.C71. PMID 23656984.

== Pharmacokinetics == Prucalopride is rapidly absorbed (Cmax attained 2–3 hours after single 2 mg oral dose) and is extensively distributed. Metabolism is not the major route of elimination. In vitro, human liver metabolism is very slow and only minor amounts of metabolites are found. A large fraction of the active substance is excreted unchanged (about 60% of the administered dose in urine and at least 6% in feces). Renal excretion of unchanged prucalopride involves both passive filtration and active secretion. Plasma clearance averages 317 ml/min, terminal half-life is 24–30 hours, and steady-state is reached within 3–4 days. On once daily treatment with 2 mg prucalopride, steady-state plasma concentrations fluctuate between trough and peak values of 2.5 and 7 ng/ml, respectively. In vitro data indicate that prucalopride has a low interaction potential, and therapeutic concentrations of prucalopride are not expected to affect the CYP-mediated metabolism of co-medicated medicinal products.

Due to Swedish law, stores in Sweden cannot sell cider with less than 15 percentage juice by volume under the name Cider. "Cider" with none or less than 15% juice is instead usually sold as "Apple/Pear beverage of cider character" (Swedish: "Äpple-/Pärondryck med Ciderkaraktär"). Brands of cider in Sweden include Rekorderlig, Kivik, Herrljunga and Kopparberg. As of 2024, there are around 30 producers of cider in Sweden. Cider beverages have a long history in Sweden since medieval times. Due to the strong impact from the Swedish temperance movement, nearly all beverages sold as cider during the 20th century were sweetened and flavoured non-alcoholic beverages similar to soft drinks. It was not until the 1990s that Systembolaget began to sell alcoholic cider. The notably sweet "Swedish cider" with flavours of apple and pear, or elderberry and wild berries, is consumed in many countries, including the United Kingdom as an alternative to traditional British cider.

There are also common comorbid psychiatric conditions with aging anorexics, including major depression, anxiety disorder, obsessive compulsive disorder, bipolar disorder, schizophrenia, and dementia. The signs and symptoms that go along with anorexia of aging are similar to what is observed in adolescent anorexia, including sudden weight loss, unexplained hair loss or dental problems, and a desire to eat alone. There are also several medical conditions that can result from anorexia in the elderly. An increased risk of illness and death can be a result of anorexia. There is also a decline in muscle and bone mass as a result of a reduction in protein intake during anorexia. Another result of anorexia in the aging population is irreparable damage to kidneys, heart or colon and an imbalance of electrolytes. Many assessments are available to diagnose anorexia in the aging community. These assessments include the Simplified Nutritional Assessment Questionnaire (SNAQ) and Functional Assessment of Anorexia/Cachexia Therapy (FAACT). Specific to the geriatric populace, the interRAI system identifies detrimental conditions in assisted living facilities and nursing homes. Even a simple screening for nutritional insufficiencies such as low levels of important vitamins, can help to identify someone who has anorexia of aging. Anorexia in the elderly should be identified by the retirement communities but is often overlooked, especially in patients with dementia.

Sources: en.wikipedia.org

Supporting material

=== Acidity === Thiols are easily deprotonated. Relative to the alcohols, thiols are more acidic. The conjugate base of a thiol is called a thiolate. Butanethiol has a pKa of 10.5 vs 15 for butanol. Thiophenol has a pKa of 6, versus 10 for phenol. A highly acidic thiol is pentafluorothiophenol (C6F5SH) with a pKa of 2.68. Thus, thiolates can be obtained from thiols by treatment with alkali metal hydroxides.

More generally, this synthesis occurs in three stages, with the first stage taking place in the cytoplasm and the second and third stages occurring in the endoplasmic reticulum. The stages are as follows:

== Stages of the CKM syndrome == The CKM syndrome is defined as having the stages listed in the following table. The table also gives the relative mortality rates of Stages 1 to 4 compared to stage 0 based on the study of 97,777 Chinese patients over a medium follow-up time of 15 years. The study found that there was a highly significant (p<0.001) increased mortality (causes not specified) with increasing stages of disease.

Sources: en.wikipedia.org

Frequently asked questions

Semax 冻干粉可以常温保存吗?

一般不建议常温长期保存。多数说明指向 -20 °C 冷冻避光。常温运输通常被视为短期可接受,但会加快降解风险。

配制好的溶液能放多久?

公开资料对此没有统一答案。普遍建议现配现用,或冷藏并在数日内用完。含甲硫氨酸的序列更易氧化,放置时间越长风险越高。

用什么方法检测 Semax 的纯度?

反相高效液相色谱是最常用的手段,配合质谱确认分子量。氨基酸组成分析和肽图分析可补充序列层面的验证。

What is Semax made of?

It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.

Network